Cargando…
675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
BACKGROUND: Current IDSA guidelines prefer Fidaxomicin for initial and first recurrent Clostridiodes difficile (C. difficile) infection. A barrier to increasing Fidaxomicin usage has been the medication’s potential high co-pay. The objective of this study was to evaluate the discharge success rate a...
Autores principales: | Cook, Ellen, Mehta, Jigar, Blecher, Alexis L, Lee, Matthew S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679246/ http://dx.doi.org/10.1093/ofid/ofad500.737 |
Ejemplares similares
-
Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012) -
Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015) -
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022) -
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013) -
Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)